Hap Trading, LLC Incyte Corp Call Options Transaction History

Hap Trading, LLC

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2021 Nov 10, 2021	BUY	$68.67 - $84.02 $1.86 Million - $2.28 Million	27,100 New	27,100 $66,000
Q1 2020 May 08, 2020	SELL	$63.18 - $85.97 $650,754 - $885,491	-10,300 Closed	0 $0
Q4 2019 Feb 11, 2020	BUY	$73.04 - $95.72 $752,312 - $985,916	10,300 New	10,300 $28,000
Q3 2019 Nov 12, 2019	SELL	$72.82 - $86.52 $771,891 - $917,112	-10,600 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$73.52 - $88.7 $1.15 Million - $1.38 Million	-15,600 Reduced 59.54%	10,600 $14,000
Q1 2019 May 10, 2019	SELL	$63.56 - $88.17 $20 Million - $27.7 Million	-314,700 Reduced 92.31%	26,200 $49,000
Q4 2018 Feb 12, 2019	BUY	$58.5 - $69.94 $280,800 - $335,712	4,800 Added 1.43%	340,900 $83,000
Q3 2018 Nov 09, 2018	BUY	$61.75 - $74.23 $13.9 Million - $16.7 Million	225,400 Added 203.61%	336,100 $524,000
Q2 2018 Aug 13, 2018	SELL	$60.85 - $83.98 $2.47 Million - $3.41 Million	-40,600 Reduced 26.83%	110,700 $242,000
Q1 2018 May 11, 2018	BUY	$83.06 - $100.98 $9.83 Million - $11.9 Million	118,300 Added 358.48%	151,300 $2.19 Million
Q4 2017 Feb 09, 2018	BUY	$93.56 - $116.6 $3.09 Million - $3.85 Million	33,000	33,000 $13,000

644

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Hap Trading, LLC with notifications on news.